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http://www.biomedcentral.com/1472-6882/13/363RESEARCH ARTICLE Open AccessKolaviron, a Garcinia biflavonoid complex
ameliorates hyperglycemia-mediated hepatic
injury in rats via suppression of inflammatory
responses
Omolola R Ayepola1, Novel N Chegou3, Nicole L Brooks2 and Oluwafemi O Oguntibeju1*Abstract
Background: Chronic inflammation plays a crucial role in hyperglycemia-induced liver injury. Kolaviron (KV), a natural
biflavonoid from Garcinia kola seeds have been shown to possess anti- inflammatory properties which has not been
explored in diabetes. To our knowledge, this is the first study to investigate the effect of KV on pro-inflammatory
proteins in the liver of diabetic rats.
Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ) (50 mg/kg) in male Wistar
rats. Kolaviron (100 mg/kg) was administered orally five times a week for six weeks. The concentrations of cytokines
and chemokine were measured using Bio-plex Pro™ magnetic bead-based assays (Bio-Rad Laboratories, Hercules, USA).
Plasma glucose and serum biomarkers of liver dysfunction were analyzed with diagnostic kits in an automated clinical
chemistry analyzer. Insulin concentration was estimated by radioimmunoassay (RIA).
Result: Kolaviron (100mg/kg) treatment significantly ameliorated hyperglycemia and liver dysfunction. Serum levels of
hepatic marker enzymes were significantly reduced in kolaviron treated diabetic rats. Kolaviron prevented diabetes
induced increase in the hepatic levels of proinflammatory cytokines; interleukin (IL)-1beta, IL-6, tumour necrosis factor
(TNF-α) and monocyte chemotactic protein (MCP-1).
Conclusion: The results of this study demonstrate that the hepatoprotective effects of kolaviron in diabetic rats may
be partly associated with its modulating effect on inflammatory responses.
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Type 1 diabetes mellitus (DM) is an autoimmune disorder
involving immune mediated recognition of pancreatic β
cells by auto-reactive T cells with subsequent release of
pro- inflammatory cytokines that worsen the disease state
[1]. DM characterized by prolonged hyperglycemia in the
postprandial and/or fasting state [2] results from impaired
insulin mediated glucose metabolism. Uncontrolled hyper-
glycemia leads to progressive development of microvascu-
lar and macrovascular complications, causing morbidity* Correspondence: oguntibejuo@cput.ac.za
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stated.and mortality in diabetic patients [3-5]. Diabetes is associ-
ated with an increased risk of hepatic injury [6,7]. It has
been reported that the standardized mortality rate from
end-stage liver disease (i.e. cirrhosis) in diabetic patients is
higher than those with cardiovascular disease [8].
To a large extent, the effect of hyperglycemia is medi-
ated by an elevation in the levels of pro-inflammatory
proteins. Over-production of several inflammatory medi-
ators such as growth factors, pro-inflammatory cytokines
and chemokines has been documented in DM [9-11].
Type 1 DM is considered as an inflammatory process
in which a significant increase of cytokines was found in
the blood of patients with this disease. The response of
hepatocytes to pro-inflammatory cytokines promotes
the expression of genes that mediate the inflammatoryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and chronic inflammation affects insulin secretion and
sensitivity [13]. Targeting inflammatory mediators sig-
naling through the use of anti-inflammatory agents
could therefore improve therapeutic options for dia-
betic liver disease, a diabetic complication that is gra-
dually gaining recognition.
Bitter kola (Garcinia kola) belongs to the family of
plants called Guttiferae and the genus Garcinia. Garcinia
kola seeds have been shown to contain a complex mixture
of polyphenolic compounds, biflavonoids, prenylated ben-
zophenones and xanthones which account for the majo-
rity of its effects [14,15]. Kolaviron (KV) is an extract from
the seeds of Garcinia kola, containing a complex mixture
of biflavonoids and polyphenols [16]. A number of studies
have confirmed the antioxidative and anti-inflammatory
effects of kolaviron in chemically-induced toxicity, animal
models of diseases and in cell culture [17-20]. Although
the glucose lowering effect of kolaviron has been reported
in animal models of diabetes mellitus [21,22], no study
has addressed the effect of KV on inflammatory bio-
markers in diabetes. In the present study, we investigated
the effects of kolaviron in modulating inflammatory
responses in the liver of streptozotocin-induced dia-
betic rats.
Methods
Plant materials
Fresh seeds of Garcinia kola were purchased from Bodija
market in Ibadan, Oyo State, Nigeria and authenticated by
Professor E. A Ayodele at the Department of Botany,
University of Ibadan. A voucher specimen is available at
the herbarium of the Forestry Research Institute of
Nigeria (FRIN), Ibadan.
Extraction of kolaviron
Garcinia kola seeds were peeled, sliced and air-dried
(25–28°C). Kolaviron was isolated according to the
method of Iwu et al. [20]. Briefly, the powdered seeds
were extracted with light petroleum ether (bp 40–60°C)
in a soxhlet for 24 hr. The defatted dried product was
repacked and extracted with acetone. The extract was
concentrated and diluted twice its volume with water
and extracted with ethylacetate (6 × 300 ml). The con-
centrated ethylacetate yielded kolaviron, a golden yellow
solid [16].
Ethics statement
The study protocol was approved by the Faculty of
Health and Wellness Sciences Research Ethics Committee
of Cape Peninsula University of Technology (Ethics Cer-
tificate no: CPUT/HW-REC 2012/AO4). All the animals
received humane care in accordance to the criteria out-
lined in the ‘Guide for the Care and Use of LaboratoryAnimals’ prepared by the National Academy of Science
(NAS) and published by the National Institute of Health
(Publication no. 80–23, revised 1978).
Animals
Adult male Wistar rats, weighing about 240–290 g were
housed in individual plastic cages at the animal facility
of the Medical Research Council, South Africa. They
were supplied with water and standard rat feed ad libitum.
The animals were maintained under standard laboratory
conditions at 22 ± 2°C with 12-h light/dark cycles and
humidity at 55 ± 5%.
Induction of diabetes
Diabetes was induced in overnight fasted rats by a single
intraperitoneal injection of a freshly prepared solution of
streptozotocin (STZ, Sigma, USA) in citrate buffer (0.1 M,
pH 4.5) at a dosage of 50 mg/kg body weight (b.wt.). Dia-
betes was confirmed by stable hyperglycemia (>18 mmol/l)
in the tail blood glucose after five days of STZ injection
using a portable glucometer (Accu-Chek, Roche, Germany).
Study design
The dose of kolaviron (100 mg/kg) was chosen based on
our preliminary investigation. 100 mg/kg kolaviron was a
more effective dose among the doses (100 and 200 mg/kg)
investigated in our preliminary study. The animals were
divided into 4 groups (n = 10 per group): Normal control
(NC group), Kolaviron treated normal control (NC +KV),
diabetic control (DM group), and kolaviron treated-
diabetic group (KV +DM group). Kolaviron (100 mg/kg b.
wt.), dissolved in dimethylsulphoxide (DMSO) was admin-
istered by gastric gavage 5 times a week. Control rats also
received DMSO as a vehicle. At the end of the treatment
period, the rats were weighed and then anaesthetized with
an intraperitoneal injection of sodium pentobarbital
(60 mg/kg). Blood glucose was measured in 4 hours-fasted
animals (usually between 10 am and 2 pm). Blood samples
were collected from the abdominal aorta into glucose
tubes (containing sodium fluoride/potassium oxalate),
EDTA-containing tubes and serum clot activator tubes.
Blood samples were centrifuged at 4000 g for 10 min at 4°C.
Aliquot of the supernatant was stored at - 80°C for plasma
glucose determination while other biochemical analysis
was carried out on the serum. The liver was dissected out,
rinsed in cold phosphate buffered saline (10 mM pH 7.2),
blotted on filter paper and weighed. Liver homogenate
was prepared in phosphate buffered saline (10 mM
pH 7.2), centrifuged at 15000 rpm for 10 min at 4°C.
Liquid chromatography-mass spectrometry (LC-MS)
analysis of Garcinia kola seed extract
LC-MS was performed on a Dionex HPLC system (Dionex
Softron, Germering, Germany) equipped with a binary
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ESI Q-TOF mass spectrometer (Bruker Daltonik GmbH,
Germany). Kolaviron was separated by reversed phase
chromatography on a Thermo Fischer Scientific C18 co-
lumn 5 μm; 4.6 × 150 mm (Bellefonte, USA) using gradi-
ent elution with 0.1% formic acid in water (solvent A) and
acetonitrile (solvent B) as solvent at a flow rate of
1.0 ml min-1, an injection volume of 10 μl and an oven
temperature of 30°C. MS spectra were acquired in nega-
tive mode using the full scan and auto MS/MS (collision
energy 25 eV) scan modes with dual spray for reference
mass solution. Electrospray voltage was set to +3500 V.
Dry gas flow was set to 9 l min-1 with a temperature of
300°C and nebulizer gas pressure was set to 35 psi.
Analysis of glucose and liver dysfunction biomarkers
Plasma glucose, levels of aspartate transaminase (AST)
and alanine transaminase (ALT) in the serum were ana-
lyzed with diagnostic kits in an automated clinical chemis-
try analyzer (Medical Cooperation, Bedford, MA, USA).
Insulin estimation
Plasma insulin was estimated by radioimmunoassay (RIA)
according to the protocol supplied by Merck Millipore
(Millipore, Cooperation, MA, USA). Separate tubes con-
taining 100 μL and 200 μL of assay buffer, 100 μL of
plasma samples or standards were mixed with100 μL 125I
insulin tracer and 100 μL of primary antibodies. The mix-
ture was incubated overnight at 4°C. This was followed by
the addition of 1 mL of precipitating agent and incubation
for 20 minutes at 4°C. Again, samples were centrifuged at
4000 g for 30 min at 4°C and the supernatant was aspi-
rated. The tubes were subjected to radioactive counting
using a 125I gamma counter.
Analysis of inflammatory biomarkers
The levels of 4 inflammatory markers including interleu-
kin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α and
monocyte chemotactic protein (MCP-1) were measured
in the tissue lysates from all the rats. This was done
using Bio-plex Pro™ magnetic bead-based assays (Bio-
Rad Laboratories, Hercules, USA) on the Bio-plex®
platform (Bio-Rad), according to the manufacturer’s in-
structions. Following previous optimization, samples
were evaluated undiluted, in a blinded manner. Bio-Plex
Manager™ software, version 6.0 was used for bead acqui-
sition and analysis.
Statistical analysis
Data were analyzed using one-way analysis of variance
and expressed as mean ± standard deviation. Statistical
analyses were performed using Graph Pad Prism version
6.02, for windows (Graph Pad software, San Diego, CA).
Differences were considered significant at P < 0.05.Results
Kolaviron treatment lowers blood glucose, prevented loss
of body weight and liver hypertrophy in diabetic rats
Effect of kolaviron administration on blood glucose, liver
and body weight in STZ-induced diabetic and normogly-
cemic rats is shown in Table 1. Six weeks after diabetes
confirmation, the random blood glucose concentration
(mmol/l) in the diabetic and control group was 28.19 ±
2.25 and 9.93 ± 0.51 respectively. The blood glucose con-
centration for the normal control rats plus KV was 8.91
± 0.6 and the diabetes mellitus plus kolaviron group was
17.35 ± 2.36. In addition to elevated blood glucose,
diabetic rats had decreased mean body weight compared
to normal control while treatment with kolaviron for
6 weeks significantly lowered blood glucose and amelio-
rated the body weight loss when compared to the un-
treated diabetic group, although body weight was still
significantly lower in comparison with normal control.
Diabetes caused an increase in relative liver weight
(expressed as % body weight) in rats while treatment of
diabetic rats with kolaviron significantly restored liver
weight to near normal. STZ diabetic rats exhibited im-
paired insulin release while KV treatment of diabetic rats
significantly increased plasma insulin levels compared
with untreated rats.
Kolaviron lowers serum levels of hepatic enzymes in
STZ-induced diabetic rats
Figure 1 indicates results of kolaviron administration on
serum levels of hepatic enzymes in STZ-induced diabetic
rats. In the diabetic group, serum levels of liver damage
biomarkers; ALT (77.96 ± 11.9) and AST (107 ± 5.43)
were elevated compared with normal controls viz: 60.37 ±
7.20 and 57.12 ± 6.63 respectively. Kolaviron administra-
tion to diabetic rats significantly reduced serum levels of
ALT (67.9 ± 6.94) and AST (53.38 ± 4.93) when compared
to diabetic control.
Kolaviron ameliorated hyperglycemia-mediated increase
in the levels of proinflammatory proteins in the liver of
diabetic rats
The effect of kolaviron on interleukin (IL)-1β, IL-6,
tumour necrosis factor (TNF-α) and monocyte chemo-
tactic protein (MCP-1) is illustrated in Figure 2. The
concentration of proinflammatory cytokines were signifi-
cantly increased in the liver of diabetic rats when com-
pared with the control rats. Lowered levels of MCP-1
and IL-1β were detected in the liver of kolaviron treated
diabetic rats compared to the untreated diabetic group.
Administration of kolaviron to diabetic rats 5 times a
week for 6 weeks also significantly reduced IL-6 and
TNF-α when compared with both normal control and
diabetic rats. Kolaviron also lowered serum levels of
TNF-α and IL-6 in normal rats.
Table 1 Effect of kolaviron administration on plasma glucose, insulin, liver weight and body weight in STZ-induced
diabetic and normoglycemic rats
Parameters NC NC + KV DM DM+ KV
Glucose (mmol/l) 9.93 ± 0.51 8.91 ± 0.6a,b 28.19 ± 2.25a 17.35 ±2.36a,b
Insulin (ng/ml) 7.99 ± 1.93 7.69 ± 1.94 0.30 ± 0.13a,b 0.79 ± 0.28a,b
Body weight change (g) +99.59 +101.12 −9.38a +45.38a,b
Relative liver weight (g) 3.22 ± 0.15 3.38 ± 0.07 4.53 ± 0.16a 3.99 ± 0.15a,b
Data are presented as mean ± S.D Values. ap < 0.05 vs. normal control. bp < 0.05 vs. untreated diabetes. NC; Normal control, NC + KV; Normal control treated with
kolaviron, DM; untreated diabetic rats, DM + KV; Diabetic rats treated with kolaviron.
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analysis of Garcinia kola seed extract
In the negative-ion, the ESI-MS analysis of kolaviron
shows molecular ion peaks [M-H]- at (1) m/z 573.1023,
(2) m/z 557.1074, (3) m/z 587.1178, (4) m/z 557.1074 (5)
m/z 541.1123 and (6) m/z 555.0909 (Figure 3). Based on
the calculated molecular formula, the presence of Garcinia
biflavonoid 2 (m/z 573.1023 = C30H22O12), Garcinia
biflavonoid 1(m/z 557.1074, 557.1072 = C30H22O11), kola-
flavanone (m/z 587.1178 = C31H24O12) and kolaflavones
(m/z 555.0909 = C30H21O11), previously reported in lit-
erature as components of kolaviron [16] were confirmed
(Figure 4a). The mass spectrum of peak 5 shows the
ion peak [M-H]- at m/z 541.1123 with the formula
C30H22O10. On the basis of this data and database
searching, the structure of this compound (peak 5) was
deduced to be a binaringenin (Figure 4b), a biflavanone
commonly found in Garcinia species [23] To our
knowledge, this is the first report of a new biflavonoid
in kolaviron (a Garcinia biflavonoid complex).
Discussion
Limitations of the currently used drugs on glycemic regu-
lation have raised the need for the development of new
drugs which can act as alternative and/or complementary
therapy. Interest in natural plant products as anti-diabetic
agents has increased over the years due to their low
side effects and multidimensional mode of action [24].N C
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Figure 1 Effect of kolaviron administration on serum levels of hepatic
as mean ± S.D values. ap < 0.05 vs. normal control. bp < 0.05 vs. untreated
kolaviron, DM; untreated diabetic rats, DM + KV; Diabetic rats treated with kKolaviron a natural compound from the bitter kola seed,
containing a complex mixture of Garcinia biflavonoid,
GBI, GB2 and kolaflavones has been demonstrated for its,
hypoglycemic, antioxidative, anti-inflammatory and anti-
genotoxic effects [19,25].
The concept that chronic low grade inflammation is
important in the development and progression of diabetes
and its associated complication is not new. Prolonged
hyperglycemia can generate an inflammatory state leading
to an increment in cytokine production and pancreatic
beta cell destruction [26]. Anti-inflammatory agents have
been documented to be beneficial in diabetes. Among
these are curcumin and its derivative [27,28], resveratrol
[29] and cannabidiol [30]. The damaging effect of inflam-
matory molecules in diabetes can be mediated through its
interaction with receptors and activation of signaling path-
ways which exacerbate the disease state [31]. Due to the
existing association between chronic inflammation and
diabetic complications including liver injury, identification
of therapeutic targets that is able to specifically downregu-
late proinflammatory responses and mediators could be a
promising strategy in the management of diabetes melli-
tus. It is noteworthy that our study is the first to investi-
gate the effect of kolaviron on inflammatory mediators in
diabetes.
Regulation of blood glucose either in the fasting state
and/or postprandially is an important factor in diabetic
therapy. Sustained glycemic control decreases the risk ofN C
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enzymes in diabetic and normoglycemic rats. Data are presented
diabetes. NC; Normal control, NC + KV; Normal control treated with
olaviron.
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Figure 2 Effects of kolaviron on levels of MCP-1, IL-1β, TNF-α and IL-6 in the liver of normal and diabetic rats. Data are presented as
mean pg/g wet tissue ± S.D. ap < 0.05 vs. normal control. bp < 0.05 vs. untreated diabetes. NC; Normal control, NC + KV; Normal control treated
with kolaviron, DM; untreated diabetic rats, DM + KV; Diabetic rats treated with kolaviron.
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tions [32,33]. The marked reduction of blood glucose in
this study following KV treatment is in line with previ-
ous studies demonstrating its hypoglycemic effects [34].
Although kolaviron significantly increased the plasma in-
sulin levels in diabetic rats, the magnitude of increase is
lower compared to the corresponding effect on blood
glucose. The mechanisms of hypoglycemic effect of kola-
viron might be due to the combination of its stimulating
action on the pancreatic β cells to release insulin and
also an insulin independent effect and extrapancreatic
action which involves glucose utilization in extrahepatic
tissues [35,36]. Furthermore, the hypoglycemic effect of
flavonoids can be mediated through an increase in
hepatic glucose storage by stimulating the action of
glycolytic and glycogenic enzymes or by inhibiting
glucose-6-phosphatase. This consequently results in the
uptake of glucose into cells and the reduction in the
blood glucose level through the upregulation of glyco-
gen formation, downregulation of the rate of glycogen
breakdown, and glucose synthesis [37-39].
It has been shown that absolute or relative insulin de-
ficiency coupled with decreased ATP production ac-
counts for low protein synthesis [40]. The decreased
mean body weight in diabetic rats could be an indicationof excessive breakdown of structural proteins in an at-
tempt to compensate for low availability of carbohydrate
as an energy source [41]. The ability of kolaviron to pro-
tect against weight loss might be due to its glucose lower-
ing effect. Liver hypertrophy (increased liver weight)
observed in diabetic rats may be due to hypoinsulinemia-
induced increased triglycerides accumulation in the liver
as alternative glucose precursors since liver glycogen is
usually depleted in STZ-induced diabetic rats [42]. Liver
weight (expressed as a percentage of body weight) was sig-
nificantly lower in kolaviron treated rats. The ability of
kolaviron to restore liver glycogen levels may partly ex-
plain its beneficial effect on liver hypertrophy in diabetic
rats. It was reported in a previous that kolaviron inhibited
microsomal glucose-6-phosphatase in STZ diabetic rats
[34]. The inhibition of glucose-6 phosphatase by kolaviron
can increase hepatic glucose-6 phosphate which serves as
substrate for glycogen synthesis thereby resulting in
upregulation of hepatic glycogen levels.
Amino transferases, aspartate transaminase (AST) and
alanine transaminase (ALT) catalyse amino transfer reac-
tions and are used as markers of hepatic injury [43]. Dele-
terious effect of hyperglycemia in the liver of diabetic rats
observed in the present study is evidenced by serum eleva-
tion of liver damage biomarkers. The hepatoprotective
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Figure 3 Mass Spectra of kolaviron. (1) Garcinia biflavonoid 2 (C30H22O12, m/z 573.1023); (2) Garcinia biflavonoid 1 (C30H22O11, m/z 557.1074);
(3) Kolaflavanone (C31H24O12, m/z 587.1178); (4) Garcinia biflavonoid 1 (C30H22O11, m/z 557.1074); (5) X (C30H22O10, 541.1123), deduced to be
binaringenin); (6) Kolaflavone (C30H21O11, m/z 555.0909).
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Figure 4 Chemical structure of Garcinia biflavonoid complex.
(Kolaviron) containing Garcinia biflavonoid GB-1(3″,4′,4‴,5,5″,7,7″-
heptahydroxy-3,8″ biflavanone), GB-2 (3″,4′,4‴,5,5″,5‴,7,7″-octa-
hydroxy-3,8″- biflavanone), and kolaflavanone (3″,4′,4‴,5,5″,5‴,7,7″
octahydroxy-4‴-methoxy-3,8″-biflavanone) is confirmed (Figure 4a)
while binaringenin (Figure 4b) is presumed to be an additional
compound in kolaviron based on ESI-MS/MS result.
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duction of serum levels of ALT and AST in the diabetic
treated rats.
Inflammation has been reported to cause direct organ
damage in diabetic rats [44,45] and humans [46]. In-
creased levels of pro-inflammatory cytokines MCP-1, IL-
1β, IL-6, IL-18 and TNF-α have been reported in diabetes
[47,48]. In this study, upregulated levels of these pro-
inflamatory proteins were observed in the liver of STZ-
induced diabetes rats.
MCP-1 is a chemo-attractant which promotes mono-
cyte and macrophage migration and activation at the site
of injury. Over-expression of MCP-1 exerts various dam-
aging effects via increased production of superoxide ra-
dicals from macrophages, release of lysosomal enzymes,
cytokines, growth factors and cellular adhesion mole-
cules [49,50]. Animal and human studies have also
shown a correlation between blood and hepatic levels of
MCP-1 and the extent of inflammation [51,52]. Consi-
dering the role of macrophages in perpetuating hepatic
inflammation, reduction of MCP-1 levels may be an-
other mechanism by which kolaviron mediates its pro-
tective effect in the liver of diabetic rats.
Hepatic infiltrating macrophages and Kupffer cells are
sources of pro-inflammatory cytokines such as TNF-α,
IL-1 and IL-6 in the liver [53]. Our study shows upregu-
lated levels of these inflammatory proteins in a diabetic
state while kolaviron treatment notably reduced hepaticlevels of IL-1β, IL-6 and TNF-α in diabetic rat. The sup-
pressing effect of kolaviron on serum levels of IL-1β has
been demonstrated in chemically-induced inflammation
of the colon [19]. IL-1β induces the expression of vari-
ous genes encoding oxidants, cytokines, chemokines,
growth factors and adhesion molecules whose promoter
region are monitored through interactions with tran-
scription factor, NFκB [54-56]. IL-1β inhibits β- cell
function and promotes Fas-triggered apoptosis in part
by NF-κB [57]. In a GK rat model of type 2 diabetes,
treatment with IL-1 receptor antagonist (IL-1Ra) re-
duced islet mRNA expression of a number of inflamma-
tory factors which includes: IL-1β, IL-6, TNF-α, MCP-1
and MIP-1α [58]. Possible mechanism by which kola-
viron elicit its liver protective and anti-inflammatory ef-
fect in diabetic rats could be by a direct reduction of
macrophage infiltration and/or by repressing NF-κB
activation.
TNF-α is one of the major cytokines upregulated in
diabetic liver which can promote the activation of NF-κB
through interaction with the TNF-α receptor resulting in
liver inflammation and apoptosis [55]. The involvement of
TNF in alcoholic hepatitis, viral hepatitis and ischemia/
reperfusion liver injury has also been documented [59].
Our study revealed that Kolaviron treatment abrogated
hyperglycemia induced increase in the hepatic concentra-
tion of TNF-α. There is a report that kolaviron (KV) shows
inhibitory action on prostaglandin E2 and TNF-α produc-
tion in macrophage-like cell line [60]. Kolaviron also down-
regulates iNOS and COX-2 expression in the liver of
dimethyl nitrosamine (DMN)-treated rat via the inhibition
of DNA binding activity of NF-κB [61]. The anti inflamma-
tory and hepatoprotective effect observed in our study
might be mediated via inhibition of transcription factor
NF-κB, a key regulator of inflammatory process.
Although the results of our study demonstrated the
beneficial effects of kolaviron on inflammatory response
and hepatic injury in the liver of diabetic rats, future
studies can address other possible mechanisms of action
of kolaviron and the underlying molecular targets of
Garcinia biflavonoid complex in diabetes. Further inves-
tigation may also be necessary for complete elucidation
of the structure of kolaviron.
Conclusion
In summary, our study revealed that kolaviron treatment
ameliorated hyperglycemia-induced increase in the levels
of proinflammatory cytokines and chemokine in rat’s
liver and may therefore act as a useful agent in retarding
the progression of diabetic liver complications. Another
important outcome of this study is the discovery of a
new compound from kolaviron. This new compound
along with previously identified compounds of kolaviron
may partly explain its beneficial effects in diabetes.
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